Currently out of the existing stock ratings of Salim Syed, 116 are a BUY (75.32%), 38 are a HOLD (24.68%).

Salim Syed

Work Performance Price Targets & Ratings Chart

Analyst Salim Syed, currently employed at MIZUHO, carries an average stock price target met ratio of 62.71% that have a potential upside of 46.75% achieved within 264 days.

Salim Syed’s has documented 296 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BIIB, Biogen at 21-Nov-2024.

Wall Street Analyst Salim Syed

Analyst best performing recommendations are on NKTX (NKARTA ).
The best stock recommendation documented was for NKTX (NKARTA ) at 11/16/2023. The price target of $9 was fulfilled within 53 days with a profit of $6.64 (281.36%) receiving and performance score of 53.09.

Average potential price target upside

of $99 (76.1%) on ATRA (ATARA BIOTHERAPEUTICS).
of $26.8 (39.65%) on PCVX (VAXCYTE ).
of $26.17 (50.52%) on CRSP (CRISPR THERAPEUTICS AG).

AMGN Amgen ASMB Assembly Biosciences BBIO BridgeBio Pharma BIIB Biogen BMY Bristol-Myers Squibb Company CELG Celgene CYTK Cytokinetics GILD Gilead Sciences NKTX Nkarta UBX Unity Biotechnology WVE Wave Life Sciences Ltd ATRA Atara Biotherapeutics CHRS Coherus BioSciences CRSP Crispr Therapeutics AG PCVX Vaxcyte

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Terence Flynn (MORGAN STANLEY)